CN1337877A - Method of preparing stable suspension of insoluble microparticles - Google Patents

Method of preparing stable suspension of insoluble microparticles Download PDF

Info

Publication number
CN1337877A
CN1337877A CN99815644A CN99815644A CN1337877A CN 1337877 A CN1337877 A CN 1337877A CN 99815644 A CN99815644 A CN 99815644A CN 99815644 A CN99815644 A CN 99815644A CN 1337877 A CN1337877 A CN 1337877A
Authority
CN
China
Prior art keywords
surface modifier
hlb
micron
phospholipid
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN99815644A
Other languages
Chinese (zh)
Other versions
CN1213733C (en
Inventor
S·坎
I·帕里克
H·C·洛克雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTP Pharma Corp
Original Assignee
RTP Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTP Pharma Corp filed Critical RTP Pharma Corp
Publication of CN1337877A publication Critical patent/CN1337877A/en
Application granted granted Critical
Publication of CN1213733C publication Critical patent/CN1213733C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sub-micron and micron-size stable particles of water-insoluble or poorly soluble drugs or other industrially useful insoluble compounds suspended in an aqueous medium containing at least one surface modifier are prepared by selecting the surface modifier or modifiers such that the hydrophile-lipophile balance (HLB) of the composition, defined as formula (I): is between 4 and 9. This provides a reliable HLB-based selection criteria for selecting the type and amount of surface modifiers used to obtain sub-micron size stable suspensions.

Description

The method for preparing the suspension of stable particulate matter
The present invention relates to produce the compositions and the method for submicron and micron big or small stable particle, this granule is water insoluble or is slightly soluble in medicine or other insoluble compound with industrial application value of water.The present invention provides reliably first based on the choice criteria of HLB, uses this standard can select to be used to obtain kind and the consumption of the surface modifier of submicron stable suspension.
Background of the present invention
People have proposed various schemes, attempt to adopt surface modifier to prepare the insoluble drugs prescription in aqueous solution, and the surface modifier that is adopted is the conjugate such as independent phospholipid or phospholipid and one or more surfactants.Yet, do not deliver the standard of any selection feature and consumption.United States Patent (USP) 5,145,684 have described a kind of microsolubility medicine, and it contains and is adsorbed on its surperficial non-crosslinked surface modifier.The amount of surface modifier is 0.1%-90% (weight), and the gained granular size is less than 400nm.United States Patent (USP) 5,298,262,5,326,552,5,336,507,5,340,564 and 5,470,583 have described the application of cloud point modifier, and microsolubility medicine wherein or diagnostic agent are adsorbed on its surface with cloud point modifier and non-crosslinked ion-type surface modifier.Cloud point modifier it is said the cloud point that can improve surfactant, thereby the growth of granular size can not appear in the gained nano-particle when carrying out heating disinfection for 121 ℃.These patents provide the example of the various specific cloud point modifier that are used in combination with the different surfaces activating agent, and wherein cloud point modification surfactant is optional.
WO98/07414 has described a kind of microsolubility medicine, and it contains two kinds and is adsorbed on its surperficial surface modifier; With only compare with a kind of modifier, adding second surface modifier makes granular size reduce nearly 50%.
EP0580690B1 has described with charged phospholipid and water-fast peptide has been carried out coating so that its solubilising, so the weight ratio of medicine and phospholipid is higher than a marginal value.Poloxamer 188 also is used to prepare drug particles when 0.01%-0.5% concentration.People observe, and when the concentration of poloxamer 188 increased, the ζ electromotive force significantly reduced.
United States Patent (USP) 5,091,187 have proposed to prepare injectable water-insoluble drug by the aqueous suspension that forms phospholipid coating microcrystal.Cause that by supersound process or other method of high shear force makes crystalline drug be reduced to 50nm-10 μ m in the presence of phospholipid.Phospholipid is used as unique surface modifier and is described.
United States Patent (USP) 5,858,410 by adopting piston clearance (piston-gap) homogenizer adding surfactant (synthetic or natural) to make the water-insoluble drug solubilising.The gained granule records its size for 10nm-1 through the photon correlation microscopy, 000nm, have account for sum less than its size of granule of 0.1% greater than 5 microns.Equally, surface modifier is chosen wantonly.
The present invention's narration
According to the compositions of the inventive method preparation, except water-insoluble or be slightly soluble in the drug particles and other industrial chemical compound of water, also comprise natural or synthetic phospholipid or the surfactant that uses separately, perhaps their uses that is bonded to each other.According to program of the present invention, with respect to the kind and the consumption of medicament selection surface modifier, so the system of this system hydrophilic-lipophile balance (HLB) value defined is as follows:
Figure A9981564400051
System HLB value is in 4 to 9 scopes.When the HLB value was in this scope, the unit weight mean particle size of resulting product was less than about 1 micron, at each temperature and all show good stable in stress test.Used terminology is meant whole compositions in this description and claims, comprises that medicine, surface modifier, carrier, excipient, diluent and other are present in the component in this based composition usually.
Hydrophilic-lipophile balance (HLB) is the balanced proportions between two kinds of opposite trends that exist in the surfactant: hydrophilic (part that glassware for drinking water is had affinity) is to lipophile (part that oil is had affinity).The hydrophilic surfactant active is many more, and then HLB value high more (surpassing 10) when the HLB of surfactant value is 1-10, then is considered to have lipophile.The HLB value of surface modifier or surface modifier system is preferably between 5 to 35.
Chemical compound water insoluble or that be slightly soluble in water can be selected from various therapeutic agents, comprises antifungal, immunosuppressant or immune activation agent, antiviral agent, antitumor agent, analgesics or antiinflammatory, antibiotic, Anti-epileptics, anesthetis, sleeping pill, tranquilizer, psychosis, psychosis, antidepressant, antianxiety drugs, anticonvulsant, antagonist, neuron blocker, anticholinergic or cholinomimetic, antimuscarinic drug or muscarine medicine, antiadrenergic, antiarrhythmics, antihypertensive, hormone or nutrient.
Used surface modifier is divided into two classes substantially usually: phospholipid and surfactant.Phospholipid can be the phospholipid or the mixture of phospholipids of any natural generation, and sometimes this paper indication is " commerce " phospholipid, and for example lecithin or soybean phospholipid perhaps are used in combination them.Phospholipid can be desalination, hydrogenant or partially hydrogenated, and is perhaps natural, semisynthetic or synthetic.The example of the commercial phospholipid that obtains includes but not limited to lecithin P123 (Pfanstiehl), Lipoid E80 (lipid) and hydrogenated soya phosphatide Phospholipon 90H and 100H (Nattennan) and 99% pure lecithin and S-PC (Avanti PolarLipids).The content of phospholipid is 0.01%-50% in the compositions, is preferably 0.05%-20%.
Surfactant is used as the second surface surface modifier sometimes, it comprises: (a) natural surfactant, for example casein, gelatin, tragakanta, wax, intestinal resin (enteric resins), paraffin, acacin, gelatin cholesterol ester and triglyceride; (b) nonionic surfactant, for example polyoxyethylene aliphatic alcohol ester, sorbitan fatty acid esters, polyoxyethylene fatty acid ester, sorbitan ester monostearin (sorbitan esters glycerolmonostearate), Polyethylene Glycol, hexadecanol, cetostearyl alcohol, octadecanol, poloxamer, poloxamines, methylcellulose, hydroxylated cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, amorphous cellulose element, polyvinyl alcohol, polyvinylpyrrolidone and synthetic phospholipid; (c) colloidal clay, for example soap clay, fillite, colloidal silica.People Remington ' s Pharmaceutical Sciences in 1986 and Theory of Practice ofIndustrial Pharmacy such as Lachman are seen in detailed description about these surfactants.
The specific examples of suitable second surface modifier comprises: poloxamer, and as PLuronic TMF68, F108 and F127, they are the oxirane of BASF production and the block copolymer of expoxy propane; Poloxamines is as the Tetronic of BASF production TM908, it is the alkyl aryl polyether sulphonic acid ester Triton that produces by four functional blocks copolymers, Rohm and Haas that continuous adding oxirane and expoxy propane in ethylenediamine obtain TMThe polyoxyethylene sorbitan fatty acid esters polysorbas20 that X-100, ICISpecialty Chemicals produce, 40,60 and 80, the Polyethylene Glycol Carbowax that produces of Union Carbide TM3550 and 934; And HYDROXY PROPYL METHYLCELLULOSE and polyvinylpyrrolidone.
Surface modifier preferably polyoxyethylene sorbitan fatty acid esters, oxirane and expoxy propane block copolymer, Myrj 45, in ethylenediamine, add four functional blocks copolymers, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose and the polyvinylpyrrolidone that oxirane and expoxy propane obtain continuously.
Ideal surfactant is the block copolymer of polyoxyethylene sorbitan fatty acid esters, Myrj 45, oxirane and expoxy propane, add four functional blocks copolymers, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose and the polyvinylpyrrolidone that oxirane and expoxy propane obtain in ethylenediamine continuously.
Phospholipid can be that be desalted, that be hydrogenated or by partially hydrogenated, and is perhaps natural, semisynthetic, synthetic, preferably phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, phosphatidyl glycerol or phosphatidic acid.
The preferred embodiment explanation
In order to further specify and describe selection course of the present invention, carried out following test.In an embodiment, use high pressure equipment under steady temperature and pressure premix to be handled, thereby make preparation be subjected to shear action, cavitation, impact and friction, this carries out in microcosmic fluidized bed plant or homogenizer.Details sees the following form.
Type of preparation Processing machine Total pass under the operating pressure Average pressure (kPsi) Mean temperature (℃)
Cyclosporin A Avestin C-50 homogenizer ????200 ????18 ????10
??Ursodiol Avestin C-5 homogenizer ????100 ????18 ????13
Benprofibratum Microcosmic fluidized bed plant M110EH ????50 ????18 ????5
" all over (pass) " is defined as the circulation of preparation by the machine each several part.Each machine " all over " or circulate as follows: Avestin C-50 homogenizer and Avestin C-5 homogenizer: preparation is placed on the inlet storage, flows to current again,, get back to the inlet storage then next through over-heat-exchanger.It is to make preparation be subjected to shearing force, cavitation, impact and friction by current.M110 EH: at first allow preparation through 20 times bypass circulation, it is defined as: the inlet storage arrives heat exchanger again to the aid in treatment assembly, gets back to the inlet storage then.Allow the gained preparation through loop, mutual chamber (interaction chember loop) again, it is defined as: the inlet storage arrives heat exchanger to the aid in treatment assembly again to mutual chamber (interaction chamber), gets back to the inlet storage then.It is to make preparation be subjected to shearing force, cavitation, impact and friction at mutual intracavity.After above-mentioned processing, each preparation is collected the phial of packing into, clog with rubbery stopper, the reuse aluminium lid covers, to be used for stability test.Acceptable granule is those microscopic particles in the 0.05-10 micrometer range.
Adopted following substances in an embodiment:
The abbreviated list of surface modifier
Full name Abbreviation
Lipid E-80 ????LipE80
Phosphatidase 11 00H ????Ph?100H
????Myrj52 ????Myrj52
Tween 80 ????Tw80
PLuronic F68 (being called poloxamer 188 again) ????PF68
PLuronic F108 (being called poloxamer 338 again) ????PF108
PLuronic F127 (being called poloxamer 407 again) ????PF127
????Tetronic908 ????T908
Supplier's list
Trade name Supplier/place of production
Cyclosporin A North China drugmaker, China
????Ursodiol Tokyo Tanabe, the Tokyo
Benprofibratum Laboratorio Chimico Intemazionale s.p.a, Milan, ITA
Lipid E-80 Lipoid GMBH, Ludwigshafen, Germany
Phosphatidase 11 00H American Lecithin Company Natterman Phospholipids, Connecticut, U.S. Oxford
????Myrj52 ICI, the Wilmington City, Delaware, USA State
Tween 80 ICI, the Wilmington City, Delaware, USA State
Tetronic and PLuronic block copolymer BASF, New Jersey Mount Olive
Following five kinds of different tests are used to assess stability of formulation.
Stability test Explanation
4 ℃ Embodiment is stored in 4 ℃ (control temperature)
25 ℃ Embodiment is stored in 25 ℃ (control temperature, 60% relative humiditys)
40 ℃ Embodiment is stored in 40 ℃ (control temperature)
Vibration Under ambient room temperature embodiment is sidelong on the vibration table, hunting speed is 100rpm-110rpm.
Thermal cycle A circular definition is: embodiment stored 1-2 days down at 4 ℃, stored 1-2 days down at 40 ℃ again.
If can satisfy at least two in the following condition, then said preparation is considered to stable:
(1) during 4 ℃ of following 4 weeks, mean particle size is less than 1.5 μ m.
(2) during 25 ℃ of following 4 weeks, mean particle size is less than 1.5 μ m.
(3) during 40 ℃ of following 1 weeks, mean particle size is less than 2.5 μ m.
(4) through after the vibration in 7 days, mean particle size is less than 1.5 μ m.
(5) through after 3 thermal cycles, mean particle size is less than 1.5 μ m.
Embodiment A
In this embodiment, assessed of the influence of system HLB value to the granular size and the stability of Cyclosporin A microgranule.We find to make system HLB value greater than 9 o'clock, gained preparation instability when phospholipid is used in combination with a kind of surface modifier.Yet when selecting system HLB value less than the combination of 9 (but greater than 0) for use, the gained preparation is a sub-micron, is stable.There is not the controlled trial of surface modifier to be used as with reference to having comprised yet.
Table 1.1 Cyclosporin A 5%w/w
Embodiment No. 1, surface modifier No. 2, surface modifier Size (μ m) Pass System HLB
Kind ??％w/w ???HLB Kind ??％w/w ???HLB
????1 ???- ????- ????0 ??- ????- ????0 ??8.33 ??138 ??0
????2 ?LipE-80 ????10 ????7 ??- ????- ???- ??2.86 ??187 ??14
????3 ?LipE-80 ????9 ????7 ?PF68 ????1 ???29 ??1.77 ??177 ??18.4
????4 ?Ph?100H ????2 ????6 ?Tw80 ????2 ???15 ??1.04 ??180 ??8.4
Above-mentioned preparation be with the amounts of 200 grams separately in batches in Avestin C-50 18, the 000psi operating pressure down preparation and.Before homogenize, the NaOH that adds 5.5%w/w mannitol and 1N is adjusted in pH value between the 7-8.Granular size is the average volume density of being measured by Malvern Mastersizer.The mean particle size of embodiment 1 during homogenize is 7 μ m-9 μ m.Even showing through granule after 180 times, the data extrapolation still remains in this scope.
The stable embodiment 4 of table 1.2-Cyclosporin A microgranule
Through the preparation after the 211 times processing; Final size be 1.00 μ m temperature (℃) final big or small (micron) natural law 4 1.00 0.81 56 25 1.00 0.80 82 of initial size (micron)
From the above-mentioned data of the embodiment 2 of table 1.2 and embodiment 3 as can be known, Lipoid E-80 is used in combination with Pluronic F68, the total w/w% that makes surface modifier can not obtain stable submicron preparation at 10% o'clock, and the gained system HLB value of these preparations is greater than 9.Embodiment 4 has illustrated and has adopted the appropriate combination of phospholipid and surface modifier that system HLB value is reduced to 8.4 that this just can obtain the stabilization formulations of sub-micron.
Embodiment B
Next studied of the influence of system HLB value to the granular size and the stability of ursodiol microgranule.These experiments (by the prepared in batches of 50 grams with 5.5%w/w mannitol) show when phospholipid is used in combination with one or more surface modifiers, make system HLB value greater than 9 or less than 4 o'clock, gained preparation instability.Yet when the combination of selecting for use system HLB value between 4-9, the gained preparation is a sub-micron, is stable.There is not the controlled trial of surface modifier to be used as with reference to being included yet.
Table 2.1-URSODIOL 10%w/w+2 surface modifier
Embodiment No. 1, surface modifier Surface modifier number Whether stable
Kind ???％w/w ???HLB Kind ??％w/w ??HLB Size (μ m) Pass System HLB
??1 ???- ?????- ????0 ???- ????- ????0 ????12.61 ????0 * ????0 No
??2 ?LipE80 ????2.4 ????7 ???- ????- ????- ????1.40 ????105 ????1.7 No
??3 ?LipE80 ????6 ????7 ???- ????- ????- ????0.99 ????104 ????4.2 Be
??4 ?LipE80 ????6 ????7 ??PF68 ????2 ????29 ????131 ????107 ????10 No
??5 ?LipE80 ????3.8 ????7 ??PF68 ????2 ????29 ????0.99 ????106 ????8.5 Be
??6 ?LipE80 ????1.6 ????7 ??T908 ????0.8 ????31 ????1.15 ????107 ????3.6 No
Ursodiol 10%w/w+3 surface modifier
Embodiment Surface modifier 1 Surface modifier 2 Surface modifier 3
Kind, %w/w ???HLB Kind, %w/w ????HLB Kind, %w/w ?HLB Size (μ m) Pass System HLB Whether stable
????7 ?LipE80，6.1 ????7 ????Myrj52，2 ????16.9 ??PF68，1.1 ??29 ????1.35 ??102 ????11.6 No
*When not having surface modifier, mixed phase produces too much foam when difficulty, and preparation can't be processed.
Table 2.2-IDD-P TMThe stability of Ursodiol is implemented 4 ℃ of 22 ℃ of 40 ℃ of 7 days 3 times examples (micron) stability of size stability stability vibration thermal cycle
Natural law size natural law size natural law size 3 0.99 28 1.03 28 1.05 7 1.07 1.05 1.075 0.99 28 1.02 28 1.03 7 1.06 1.04 1.09
Can draw following important conclusion from the result of table 2.1 and table 2.2:
The embodiment of table 2.1 1,2 and 3 has illustrated that thereby phospholipid concentration is increased to 2.4%, 6% system HLB value from 0% is increased to 1.7,4.2 result from 0 respectively.Under the situation of embodiment 1, there is not surface modifier, be difficult with medicine and water mixing, and preparation can't be by homogenize.The preparation that has greater than 4 system HLB value is a sub-micron and stable, and other preparation then is not like this.
Embodiment 3 and 4 illustrated when phospholipid concentration and has been fixed on 6%, the concentration of PF68 is increased to 2% from 0%, thereby system HLB value is respectively 4.2 and 10 result.Preparation with system HLB value of 4-9 is a sub-micron and stable, and other preparation then is not like this.
Embodiment 4 and 5 has illustrated concentration fixed as PF68 2%, content of phospholipid is reduced to 3.8% from 6%, thereby system HLB value is respectively 10 and 8.5 result.Preparation with system HLB value of 4-9 is a sub-micron and stable, and other preparation then is not like this.
Embodiment 6 and 7 has illustrated the result when system HLB value is outside the 3.9-9 scope: granular size is greater than 1 micron, and the preparation instability.Particularly the system HLB value of embodiment 5 is less than 3.9, and the system HLB value of embodiment 6 is greater than 9.
Embodiment C
Present embodiment has been studied the influence of system HLB value to the granular size and the stability of Benprofibratum.These experiments show when phospholipid is used in combination with one or more surface modifiers, make system HLB value less than 4 o'clock, gained preparation instability.Yet when the combination of selecting for use system HLB value between 4-9, the gained preparation is a sub-micron and stable.There is not the controlled trial of surface modifier to be used as with reference to being included yet.
Table 3.1-Benprofibratum 10%w/w (+5.5%w/w mannitol)
Embodiment No. 1, surface modifier No. 2, surface modifier Whether stable
Kind ??％w/w ??HLB Kind ?％w/w ??HLB Size (μ m) Pass System HLB
????1 ???- ????- ????0 ???- ????- ????0 ????65 ????0 * ????0 No
????2 ?LipE80 ????3 ????7 ???- ????- ????0 ????1.06 ????70 ????2.1 No
????3 ?LipE80 ????4 ????7 ???- ????- ????0 ????0.95 ????70 ????2.8 No
????4 ?LipE80 ????3 ????7 ??PF127 ????1 ????29 ????0.86 ????70 ????5.0 Be
????5 ** ?Ph100H ????0.83 ????6 ??PF108 ????1.67 ????29 ????0.85 ????84 ????5.3 Be
????6 ** ?Ph100H ????1.33 ????6 ??PF108 ????0.67 ????29 ????0.83 ????70 ????2.7 No
Benprofibratum 5%w/w (+5.5%w/w mannitol)
????7 ?LipE-80 ????2 ????7 ??PF127 ????0.5 ????29 ????.88 ????70 ????5.7 Be
????8 ?LipE-80 ????2.3 ????7 ??PF127 ????0.2 ????29 ????0.91 ????70 ????4.4 Be
*When not having surface modifier, mixed phase is when difficulty, and pharmaceutical suspension and can't process preparation on water.
*There is not mannitol to exist.
In the table 3.1 given preparation be with the amounts of 200 grams separately in batches in M110 EH 18, the 000psi operating pressure down preparation and.Before homogenize, the NaOH that adds 1N is adjusted in pH value between the 6-8.Granular size is the average volume density of being measured by Malvem Mastersizer.
The stability of table 3.2-Benprofibratum microgranule
Embodiment Size (micron) 4 ℃ of stability 22 ℃ of stability 40 ℃ of stability Vibration in 7 days
Natural law Size Natural law Size Natural law Size
????4 ????0.86 ????33 ????1.10 ????29 ????1.32 ????8 ????2.31 ????1.27
????5 ????0.91 ????26 ????1.1 ????26 ????1.29 ????7 ????1.68 ????1.16
????7 ????0.88 ????29 ????1.01 ????29 ????1.18 ????12 ????2.47 ????1.09
????8 ????0.91 ????35 ????1.12 ????35 ????1.25 ????7 ????1.4 ????1.04
The embodiment of table 3.1 2 and 4 has illustrated that thereby PF127 concentration is increased to 1%w/w system HLB value from 0% is respectively 2.1 and the result that produced at 5 o'clock.The preparation that has greater than 4 system HLB value is a sub-micron and stable, and other preparation then is not like this.Thereby embodiment 3 and 4 has illustrated the result that the total surface modification agent content of relative quantity that changes Lip E80 and PF127 is produced when being 4%w/w.The preparation (embodiment 4) that has greater than 4 system HLB value is stable, and system HLB value is then unstable less than 4 preparation (embodiment 3).
The result that embodiment 5 and 6 has been produced when the relative quantity that changes phosphatidase 11 00H and PF108 has been described: system HLB value is stable greater than 4 preparation (embodiment 5), and system HLB value is then unstable less than 4 preparation (embodiment 6).
Embodiment 7 and 8 is stable sub-micron preparations, and the total content of its surface modifier is 2.5%w/w, and the system HLB value of each preparation is between 4-9.In two kinds of preparations, used the various combination of Lip E80 and PF127.
Embodiment 3 and 7 illustrated when the weight ratio of Lip E80 remains on 4, and PF127 is increased to the result who was produced with respect to the weight ratio of medicine at 1 o'clock from 0.System HLB value is respectively 2.8 and 5.7.System HLB value is a sub-micron greater than 4 preparation, is stable, and other preparation is then unstable.
Embodiment D
In the table 4.1 preparation of listed present embodiment be with the amounts of 200 grams separately in batches (22 ℃ following 120 times) in M110 EH under the 18kpsi operating pressure preparation and.Granular size is the average volume density of being measured by Malvem Mastersizer.
Table 4.1-VEX5%
Embodiment Surface modifier #1 Surface modifier #2 Whether stable
Kind ??％w/w ???HLB Kind ???％w/w ???HLB Size (μ m) Pass System HLB
????1 ?LipE80 ????0.5 ????7 ??PF108 ????1.0 ????29 ????0.34 ????120 ????6.5 Be
Through after 4 weeks, granular size is 0.34 micron, and is identical with initial size under 25 ℃, and this granule is stable thus.
Embodiment in the last table 4.1 has the system HLB value between the 4-9, at room temperature (25 ℃ of following 4 weeks) show good stable.Medicine after the lyophilization (containing the 5%w/w polyvinylpyrrolidone) reconstitutes 0.37 micron, and is identical with initial size basically.In addition, this preparation demonstrates significant bioavailability for Canis familiaris L. and mouse.The bioavailability of Canis familiaris L. is 27%, and the bioavailability of mouse is 33%.

Claims (10)

1. the method for the suspension of stable, micron for preparing the chemical compound that is suspended in water insoluble in the water-bearing media that contains at least a surface modifier or is slightly soluble in water or sub-micron, this method comprises selects surface modifier so that the hydrophilic of compositions-lipophile balance (HLB) value is in 4 to 9 scopes, and system HLB is defined as follows:
2. preparation water insoluble in the water-bearing media that contains phospholipid and at least a surfactant or be slightly soluble in stable, the micron of chemical compound of water or the method for the suspension of sub-micron, thereby this method comprise the option table surface-active agent make compositions hydrophilic-lipophile balance (HLB) value is in 4 to 9 scopes, system HLB is defined as follows:
Figure A9981564400022
3. the process of claim 1 wherein that the HLB value of surface modifier is between 5 to 35.
4. the method for claim 2, wherein the HLB value of surfactant is between 5 to 35.
5. the process of claim 1 wherein that surface modifier is the block copolymer, Myrj 45 of polyoxyethylene sorbitan fatty acid esters, oxirane and expoxy propane, adds four-functional group block copolymer, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose, polyvinylpyrrolidone and the polyvinyl alcohol that oxirane and expoxy propane obtain continuously in ethylenediamine.
6. the method for claim 2, wherein surfactant be polyoxyethylene sorbitan fatty acid esters, oxirane and expoxy propane block copolymer, Myrj 45, in ethylenediamine, add four-functional group block copolymer, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose, polyvinylpyrrolidone and the polyvinyl alcohol that oxirane and expoxy propane obtain continuously.
7. the method for claim 2, wherein phospholipid is desalination, hydrogenant or partially hydrogenated, and is perhaps natural, semisynthetic or synthetic.
8. the method for claim 7, wherein phospholipid is phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, phosphatidyl glycerol, phosphatidic acid lysophosphatide, lecithin or soybean phospholipid, perhaps their combination.
9. the method for claim 1 or claim 2, chemical compound wherein water insoluble or that be slightly soluble in water is to comprise antifungal, immunosuppressant or immune activation agent, antiviral agent, antitumor agent, analgesics or antiinflammatory, antibiotic, Anti-epileptics, anesthetis, hypnotic, tranquilizer, psychosis, psychosis, antidepressant, antianxiety drugs, anticonvulsant, antagonistic, the neuron blocker, anticholinergic or cholinomimetic agent, antimuscarinic drug or muscarine medicine, antiadrenergic, antiarrhythmics, antihypertensive, hormone or nutrient.
10, pass through the Pharmaceutical composition of the method preparation of claim 1, it comprises phospholipid and surfactant, and wherein the HLB value of compositions is between 4 to 9, and it is identical that the granular size that said composition reconstitutes after lyophilization keeps basically.
CNB998156442A 1998-11-20 1999-11-19 Method of preparing stable suspension of insoluble microparticles Expired - Fee Related CN1213733C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10920398P 1998-11-20 1998-11-20
US60/109203 1998-11-20

Publications (2)

Publication Number Publication Date
CN1337877A true CN1337877A (en) 2002-02-27
CN1213733C CN1213733C (en) 2005-08-10

Family

ID=22326359

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998156442A Expired - Fee Related CN1213733C (en) 1998-11-20 1999-11-19 Method of preparing stable suspension of insoluble microparticles

Country Status (8)

Country Link
EP (1) EP1133280A1 (en)
JP (1) JP5296954B2 (en)
KR (1) KR20010075713A (en)
CN (1) CN1213733C (en)
AU (1) AU767737B2 (en)
CA (1) CA2349202C (en)
IL (2) IL143196A0 (en)
WO (1) WO2000030615A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111929133A (en) * 2011-11-30 2020-11-13 新加坡科技研究局 Microparticle polypeptide ratio of GM1 ganglioside to annexin V for biological assays
CN114367383A (en) * 2022-01-13 2022-04-19 苏州丰倍生物科技有限公司 Fatty acid ester nano suspension, preparation method and application thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1267946A4 (en) * 2000-02-28 2008-07-02 Genesegues Inc Nanocapsule encapsulation system and method
AR035642A1 (en) 2000-05-26 2004-06-23 Pharmacia Corp USE OF A CELECOXIB COMPOSITION FOR QUICK PAIN RELIEF
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
FR2819720B1 (en) 2001-01-22 2004-03-12 Fournier Lab Sa NEW FENOFIBRATE TABLETS
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (en) 2001-09-26 2004-10-13 Baxter Int Preparation of submicron sized nanoparticles by dispersion and solvent or liquid phase removal
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651680B1 (en) * 1989-09-14 1991-12-27 Medgenix Group Sa NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES.
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE69734988T2 (en) * 1996-08-22 2006-09-21 Jagotec Ag PREPARATIONS CONTAINING MICROPARTICLES OF WATER-INSOLUBLE SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF
WO1999049846A2 (en) * 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
JP2002516267A (en) * 1998-05-29 2002-06-04 アールティーピー・ファーマ・インコーポレーテッド Thermally protected particulate composition and its final steam sterilization

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111929133A (en) * 2011-11-30 2020-11-13 新加坡科技研究局 Microparticle polypeptide ratio of GM1 ganglioside to annexin V for biological assays
CN114367383A (en) * 2022-01-13 2022-04-19 苏州丰倍生物科技有限公司 Fatty acid ester nano suspension, preparation method and application thereof
CN114367383B (en) * 2022-01-13 2024-01-09 苏州丰倍生物科技股份有限公司 Fatty acid ester nano suspension, preparation method and application thereof

Also Published As

Publication number Publication date
KR20010075713A (en) 2001-08-09
JP5296954B2 (en) 2013-09-25
AU1737400A (en) 2000-06-13
WO2000030615A1 (en) 2000-06-02
CA2349202A1 (en) 2000-06-02
IL143196A0 (en) 2002-04-21
JP2002530320A (en) 2002-09-17
EP1133280A1 (en) 2001-09-19
AU767737B2 (en) 2003-11-20
IL143196A (en) 2012-01-31
CN1213733C (en) 2005-08-10
CA2349202C (en) 2012-06-19

Similar Documents

Publication Publication Date Title
CN1303985C (en) Compositions comprising microparticles of water-insoluble substances and method for preparing same
CN1303278B (en) Method for preparing compositions of microparticles of water-insoluble substances
US8206746B2 (en) Microparticles of water-insoluble substances
CN1213733C (en) Method of preparing stable suspension of insoluble microparticles
US6337092B1 (en) Composition and method of preparing microparticles of water-insoluble substances
CN1761454A (en) Method for preparing small particles
CN1870987A (en) Method for preparing submicron particles of antineoplastic agents
CN1905905A (en) High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
CN1794975A (en) Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
AU3404900A (en) Compositions comprising microparticles of water-insoluble substances
CN1764438A (en) Methods and apparatuses for the comminution and stabilization of small particles

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050810

Termination date: 20151119